Objective: It has been reported that a failed endovascular intervention adversely affects results of lower extremity bypass (LEB). We reviewed rates of prior endovascular intervention (PEI) in patients undergoing LEB with autologous vein for critical limb ischemia (CLI) to determine effects on graft patency, limb salvage, and amputation-free survival. Methods: Retrospective review was conducted of consecutive autologous vein LEBs performed for CLI between 2005 and 2012 at a tertiary care academic medical center. Results: Overall, 314 autologous vein LEBs were performed for CLI, 71% for tissue loss. TransAtlantic Inter-Society Consensus II type D or type C lesions were present in 62% and 25%, respectively. The great saphenous vein was used as a conduit in 83%, and the distal target was infrapopliteal in 60%. The 30-day mortality rate was 3.5%. Primary patency rates at 1 year and 5 years were 61% and 45%. Secondary patency rates at 1 year and 5 years were 88% and 64%, with 23% requiring an intervention to maintain patency. The 5-year limb salvage rate was 89%, and the 5-year amputation-free survival was 49%. There were 61 patients (19%) who had undergone a PEI and 253 (81%) who underwent bypass with no prior endovascular intervention (NPEI). There were 19 iliac stents, 29 femoral interventions, 13 popliteal interventions, 9 crural interventions, 9 infrainguinal thrombectomies, and 13 infrainguinal thrombolyses. PEI and NPEI patients had similar demographics and prevalence of atherosclerotic risk factors. The 1-year primary patency rate was 62% for NPEI patients vs 59% for PEI patients (P [ .759). The 1-year and 2-year secondary patency rates were 87% and 79% for NPEI patients vs 89% and 78% for PEI patients (P [ .947). The 3-year limb salvage rate was 89% for NPEI patients vs 92% for PEI patients (P [ .445). The 3-year amputation-free survival was 59% for NPEI patients vs 52% for PEI patients (P [ .399). Median follow-up time was 323 days for NPEI patients (interquartile range, 83-918) vs 463 days for PEI patients (interquartile range, 145-946; P [ .275). Conclusions: Overall operative mortality, patency rates, and limb salvage for autologous vein LEB in CLI patients continue to be excellent in the endovascular era and are not necessarily affected by a prior ipsilateral endovascular procedure. Long-term survival remains poor in CLI patients requiring LEB. (J Vasc Surg 2014;60:129-35.) 
Catheter-based interventions have expanded treatment options for patients with critical limb ischemia (CLI). When endovascular procedures fail in a patient with CLI, the alternative is frequently autogenous vein lower extremity bypass (LEB). In fact, the inevitable correlate of increased use of primary endovascular intervention is that LEBs will, of necessity, have to be performed in patients who have had prior failed endovascular interventions. [1] [2] [3] [4] Previous reports have raised concerns about the potential negative impact of failed endovascular procedures on subsequent LEB outcomes. [5] [6] [7] [8] [9] [10] It is possible, however, that a failed endovascular intervention is not necessarily associated with worse outcomes for LEB among CLI patients in all practice settings. The purpose of this study was to review the experience at our institution to determine if prior ipsilateral endovascular intervention was associated with impaired patency, limb salvage, or amputation-free survival in patients undergoing LEB for CLI.
METHODS
From a prospectively maintained vascular surgical registry, we constructed a database that included all patients who underwent LEB with autologous vein for CLI between 2005 and 2012. The time period selected for the study corresponded to the implementation of an electronic medical record system at Oregon Health and Science University and increasing use of catheter-based procedures in our practice. The study was approved by the Oregon Health and Science University Institutional Review Board and informed consent waived as this was an analysis of registry data.
Electronic medical records were retrospectively reviewed for each case to extract the following prespecified data: patient demographics, medical comorbidities, medication use, physical examination findings, prior lower extremity interventions, operative indication, results of preoperative vein mapping, operative procedure, morbidity and mortality, preoperative and postoperative angiographic results, reinterventions, and patterns of graft failure. Primary, primary assisted, and secondary patency as well as limb salvage, amputation-free survival, and overall survival were calculated by Kaplan-Meier methods.
Comorbidities were considered present when documented in chart notes. Medication use was that at the time of initial consultation for LEB for CLI. Renal insufficiency was defined as a serum creatinine concentration >1.4 mg/dL before operation. Patients were categorized as former smokers if they had quit >8 weeks before operation. Preoperative vein mapping was performed by an Intersocietal Accreditation Commissioneaccredited vascular laboratory, and measurements were taken from official diagnostic reports. Postoperative wound complications were defined according to the Szilagyi criteria.
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Major amputations were defined as those at the transtibial or transfemoral level. Toe or partial foot amputations were classified as minor amputations. Graft patency was defined according to established Society for Vascular Surgery standards. 12 Our bypass graft surveillance protocol included duplex scans every 3 months for 1 year and, depending on findings and interventions, continued short-interval scanning or once yearly at minimum. Loss to follow-up was defined as 18 months without clinic visit or correspondence. Mortality was determined from chart records and the Social Security Death Index.
Categorical variables were analyzed by c 2 or Fisher exact test. Continuous variables were analyzed by unpaired Student t-test or Mann-Whitney test. Normally distributed variables are expressed as means 6 standard deviation; nonparametric variables are expressed as medians (interquartile range). Time-to-event variables were analyzed by log-rank test of Kaplan-Meier analysis.
Analyses were performed with SPSS version 21 statistical software (IBM Corp, Armonk, NY). Significance was set at P ¼ .05 in all cases, and two-sided values were reported where applicable.
RESULTS
Between 2005 and 2012, there were 383 consecutive, autologous vein LEBs performed in 332 patients at our institution. All bypasses were performed with use of reverse vein. There were 314 LEBs performed for CLI, which make up the study population; 71% (222) were performed for tissue loss. Of the CLI patients, 63% were men. TransAtlantic Inter-Society Consensus II (TASC) type D or type C lesions were present in 191 (61%) and 79 (25%), respectively. The great saphenous vein was used as the conduit in 260 operations (83%), and the distal target was an infrapopliteal artery in 188 (60%). The 30-day mortality rate was 3.5%. To maintain patency, 72 grafts (23%) underwent a reintervention. The 1-year and 5-year primary patency rates were 61% and 45%. The 1-year and 5-year secondary patency rates were 88% and 64%. The 5-year limb salvage rate was 89%, and the 5-year amputation-free survival was 49%.
There were 61 patients (19%) who had undergone 92 prior endovascular interventions (PEIs); 253 patients (81%) had not undergone a prior endovascular intervention (NPEI). These prior interventions are detailed in Table I . The indications for these PEIs were unknown in 8 (13%), CLI in 42 (69%), and intermittent claudication in 11 (18%). At the time of bypass, 27 patients (44%) had interventions that were still patent.
Additional demographics are presented in Table II . The PEI group had a decreased prevalence of hypertension and an increased prevalence of clopidogrel use, despite similar overall antiplatelet use. The two groups were similar in other respects. Median follow-up time was 323 days for the NPEI group (interquartile range, 83-918) vs 463 days for the PEI group (interquartile range, 145-946; P ¼ .275).
Tissue loss was present in 181 NPEI patients (71.5%) and 41 PEI patients (67.2%; P ¼ .505). In the NPEI group with tissue loss, 107 wounds (59%) were in the forefoot, 30 (17%) in the hindfoot, and 27 (15%) in the lower leg. In the PEI group, 24 wounds (59%) were in the forefoot, 5 (12%) in the hindfoot, and 8 (20%) in the lower leg. These differences were not statistically significant. TASC II classifications are presented in Table III , showing a trend toward more severe occlusions in the NPEI group.
The distribution of proximal and distal anastomotic sites was not different between groups (Table IV) . The great saphenous vein was used in 215 NPEI bypasses (85%) and 45 PEI bypasses (74%) (P ¼ .005). This difference was accompanied by a roughly equivalent increase in the use of arm vein in the PEI group compared with the NPEI group, 16 (26%) vs 34 (14%), respectively (P ¼ .005). A venovenostomy was required in 35 NPEI bypasses (14%) and 12 PEI bypasses (20%) (P ¼ .251). The minimum vein diameter was 3.3 6 0.9 mm in the NPEI group vs 2.9 6 0.8 mm in the PEI group (P ¼ .009). Endoscopic vein harvest was used in 90 NPEI bypasses There were 92 PEIs performed in 61 patients.
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(36%) and 14 PEI bypasses (23%) (P ¼ .060). Mean operative times were 296 6 96 minutes in the NPEI group vs 282 6 96 minutes in the PEI group (P ¼ .324). Perioperative morbidity and mortality are presented in Table V . There was no difference between groups. Szilagyi grade I wound complications occurred in 61% of the NPEI group vs 53% of the PEI group (P ¼ .253). Szilagyi grade II occurred in 35% of the NPEI group vs 18% of the PEI group (P ¼ .628). Szilagyi grade III occurred in 4% of the NPEI group vs 13% of the PEI group (P ¼ .008). Primary LEB patency at 1 year was 61.5% for NPEI patients vs 58.8% for PEI patients (P ¼ .759) (Fig 1) . Secondary patency at 1 year and 2 years was 87.1% and 79.2% for NPEI patients vs 89.4% and 78.2% for PEI patients (P ¼ .947) (Fig 2) .
There were 76 minor amputations (30.6%) in the NPEI group and 18 (30%) in the PEI group (P ¼ .624). There were 26 major amputations (10.5%) in the NPEI group and 4 (6.7%) in the PEI group (P ¼ .588). Limb salvage at 3 years was 88.9% in the NPEI group vs 91.7% in the PEI group (P ¼ .445) (Fig 3) . Amputation-free survival at 3 years was 59.2% in the NPEI group vs 52.4% in the PEI group (P ¼ .399; Fig 4) . Overall survival was 65.3% in the NPEI group vs 56.5% in the PEI group (P ¼ .160; Fig 5) .
In the NPEI group, 55 grafts (21.7%) required an intervention to maintain or to restore patency during the study period, compared with 18 grafts (29.5%) in the PEI group (P ¼ .236). The median time to intervention was 190.5 (IQR, 82.8-285.5) days for NPEI vs 131 (IQR, 64-197.8) days for PEI (P ¼ .178). Of these 55 NPEI grafts, 31 (56.4%) ultimately required operative intervention compared with 13 of 18 revised PEI grafts (72.2%; P ¼ .277).
Because some would argue that the inclusion of iliac stents biases the outcomes of the PEI group, we performed the same analysis excluding the 16 patients whose most distal intervention was an iliac stent. The primary demographic results reported before were essentially unchanged. There was an increased prevalence of hypertension diagnosed in the NPEI group. The NPEI group was more likely to have a bypass with saphenous vein, and those veins were larger on average. Otherwise, there were no significant differences between groups. The 1-year primary patency was 61% for NPEI patients vs 56% for PEI patients (P ¼ .580). The 2-year secondary patency was 78% for NPEI patients vs 74% for PEI patients (P ¼ .740). Limb salvage was 91% for both NPEI and PEI groups at 2 years. Amputation-free survival was 59% for NPEI patients vs 52% for PEI patients at 3 years (P ¼ .466). Overall survival was 65% vs 59% at 3 years (P ¼ .346). 
DISCUSSION
The goal of our study was to determine whether PEI was associated with inferior outcomes for LEB performed for CLI. With respect to patency, graft-directed reintervention, limb salvage, amputation-free survival, and survival, we could find no statistical differences in our patients who underwent LEB for CLI before or after a catheterbased intervention for lower extremity ischemia.
There are no randomized trials directly addressing the effect of previous catheter-based interventions on subsequent LEB for CLI. Results of the Bypass vs Angioplasty in Severe Ischaemia of the Leg (BASIL) trial most closely approximate a randomized trial to address the effects of catheter interventions on subsequent LEB for CLI. Aiming to compare an endovascular-first with a bypass-first approach for CLI, the trial randomized 452 patients to percutaneous transluminal angioplasty (PTA) or autologous vein LEB; 37 patients randomized to PTA had early failures and ultimately required LEB. Compared with those who had a primary bypass performed after randomization, these 37 suffered inferior amputation-free survival rates. 13 Consistent with the analysis of the BASIL trial, a number of other investigators have also found inferior results for LEB after endovascular interventions. Most other studies are, however, also quite small. Bockler et al 14 reported worsening clinical ischemia and inferior patency rates in a series of 18 patients who received a bypass after failed infrainguinal stenting compared with a selected comparison group of contemporary primary bypasses. In 2008, Joels et al 15 reported on early failures in 23 of 276 patients undergoing endovascular interventions of the superficial femoral artery. Of those, 28% had a change in ideal distal anastomotic site as judged by blind review of preintervention and postintervention angiograms by three vascular surgeons. Although statistically insignificant, a trend was noted toward inferior patency, limb salvage, and runoff quality in those patients who had alteration of the distal anastomotic site. CLI patients were also more likely to have alteration of their ideal distal anastomotic site compared with intermittent claudication patients (42% vs 11%).
In the largest series of which we are aware, there was a roughly 50% increased risk in graft occlusion or amputation among 132 bypasses performed after endovascular intervention compared with 1277 bypasses performed in the absence of prior endovascular revascularization. 16 However, this series from the Vascular Study Group of New England reflects regional results from many hospitals and does not necessarily reflect what can or will be achieved in all practice settings.
There are also prior studies arguing against a negative impact of PEIs on LEB. All are retrospective series. Parsons et al 6 reported a series of 307 PTAs in 257 CLI patients; 59 went on to LEB. The 1-year patency of these LEBs was more than 70%, which compares favorably with our results and previously published data. [17] [18] [19] Ryer et al 7 described 251 patients (42% with CLI) treated with primary PTA with or without stenting. Five ultimately required bypass, and they claim that the ability to perform the bypass was not affected; however, no long-term outcomes were reported. Dosluoglu et al 5 compared outcomes for a large series analyzing an endovascular-first vs bypass-first approach to CLI patients. They had 22 endovascular-first patients who ultimately required a bypass. In this group, three required amputation for an amputation rate of 14%, which was equivalent to the amputation rate of the overall group. They concluded that bypass after endovascular intervention is a rare event and is not adversely affected by endovascular intervention. These studies are joined by others suggesting minimal impact of failed endovascular intervention on LEB and infrequent impact on distal anastomotic sites, although the numbers are small. [8] [9] [10] A strength of our study was that apart from the PEI group's having an increased baseline prevalence of clopidogrel use, group demographics were otherwise well matched. There was a similar prevalence of tissue loss and the level at which it was present between groups. Operative conduct was also well matched, with similar proximal and distal anastomotic sites in both groups. Ultimately, our patency rates were comparable to prior randomized data, such as those provided in the PREVENT III trial. 17 The 1-year primary patency rate for our cohort was identical to that reported in the trial, 61%. The 1-year secondary patency rate was 80% in PREVENT III, whereas our overall secondary patency rate at 1 year was 88%.
Factors that were not well matched and could have confounded comparisons between groups included venous conduit characteristics and preoperative disease burden. The PEI group more frequently required arm vein as a conduit, and minimum vein diameter on preoperative vein mapping was 0.4 mm smaller. In our patients, these differences would have been expected to lead to worse outcomes in the PEI group. Conversely, the NPEI group appeared to have more severe atherosclerotic burden at baseline on the basis of angiographic features, with a trend toward increased prevalence of TASC type D lesions.
We acknowledge that our study was not a prospective randomized trial. This allows a number of inherent biases, most apparent being patient selection. However, there are also no prior studies designed or randomized to specifically determine whether an endovascular intervention negatively affects subsequent LEB, thus subjecting them to potentially the same biases. Our study argues that with appropriate patient selection, results of LEB are not necessarily impaired by PEI. Endovascular intervention should not be avoided solely for concerns about the effect on subsequent LEB bypass should the endovascular intervention fail. However, achieving these results is likely to require very careful preoperative planning, including angiography and vein mapping; experience with alternative vein conduits and composite vein conduits; and willingness to perform revisions for graft defects identified with postoperative graft surveillance.
The category of "prior endovascular interventions" captures a heterogeneous population. We included patients with prior iliac stenting in our primary analysis to capture all patients who received prior endovascular treatment, whereas other studies specifically excluded suprainguinal interventions. A separate analysis excluding iliac stents did not change our primary results.
It was not possible to know procedural details of the PEIs in all patients as many of these interventions were performed at a referring hospital. It is certainly possible that different types and extents of endovascular intervention could have a variable impact on subsequent LEB. Our approach to catheter-based interventions for CLI is admittedly conservative. We consider LEB for CLI to be a good operation and therefore have not likely subjected our patients to highly aggressive catheter-based procedures that could be associated with a great likelihood of impairing the performance of subsequent LEB. Any patient who is a reasonable operative candidate with TASC type C or D disease and has vein available for conduit is preferentially offered a bypass.
Our analysis also only considered patients who actually underwent bypass. It is certainly possible that some patients with a PEI and continuing or new CLI were treated with primary amputation or with nonoperative therapy. What our data show is that when a patient with a prior catheterbased intervention undergoes lower extremity autogenous vein reverse bypass at our institution, the result is not likely to be any different from that in patients at our institution who undergo LEB for CLI without PEI. Use of PEIs does not have to impair the results of subsequent LEB for CLI.
CONCLUSIONS
In a patient population treated for CLI with reversed vein LEB, PEI was not associated with a negative impact on mortality, patency, or limb salvage. Equivalent outcomes for LEB performed for CLI can be achieved in both NPEI and PEI patients. The exact circumstances under which such results can be achieved is a subject for further study. Why the disparity? Almost 30% of endovascular-first patients reported in the Oregon series had iliac PTA, a procedure that is quite unlikely to adversely impact LE bypass and in fact might even be beneficial (or have been planned in a staged hybrid approach to limb salvage). What percentage of your patients had endo by your own group (as opposed to endo performed elsewhere prior to referral)? Dr Vincent J. Santo. Twenty-one of 61 patients had their endovascular intervention at OHSU prior to bypass. Forty patients had their endovascular intervention prior to referral to OHSU.
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Dr Mills. What was mean time from EVT to bypass? Delays in achieving adequate perfusion after inadequate revascularization in patients with wounds can lead to larger wounds and often superimposed infection. We know from Eurodiale and others report that infection triples amputation risk in patients with PAD and that persistence or nonhealing of wounds increases risk of infection.
Dr Santo. We do not have information on the time lapse between the endovascular intervention and subsequent bypass because for those patients treated outside the OHSU system, this information was either imprecise or entirely unavailable.
Dr Mills. Did you specifically examine patients who had undergone prior SFA stents? Ihnat et al reported that SFA stent occlusion worsened SVS runoff score, leading to a net loss of one runoff vessel per failed stent. Could you determine whether a previous endovascular procedure impacted target site for bypass (eg, converted fem-pop to fem-tib target)?
Dr Santo. We did not analyze the subset of patients who received SFA stenting, as this only included eight patients and we felt any statistical analysis would be underpowered. We also did not attempt to analyze any changes in "best distal target" again because the majority of patients were treated prior to arriving in the OHSU system and we did not have baseline angiographic data.
Dr Mills. Finally, there were relatively few tibial interventions. Were there any pedal interventions? There are reports from Italy of adverse impact on pedal bypass after failed tibial/pedal interventions. In the U.S., Vogel et al reported in 2011, using a Medicare database of 13,258 interventions for CLI, that tibioperoneal angioplasty was associated with frequent in-hospital complications, an overall 30-day amputation rate of 23.8% for all procedures and indications, and a 30-day rehospitalization rate of almost 30%. 1 The relative aggressiveness of EVT in the Pacific Northwest seems remarkably low.
Dr Santo. There were no endovascular pedal interventions performed in this patient population.
Dr Mills. Do you have any data on patients who underwent amputation after failed EVT without bypass? It seems to me you would need that data and that such patients would be systematically excluded from your series.
Dr Santo. Unfortunately, we do not have that data available yet. We know that roughly 700 interventional and 700 diagnostic angiograms were performed at OHSU during the same study period, but the details of these interventions have not yet been extracted. This is the subject of a future study and we agree, it will be very interesting to know the outcome of these interventions to better understand the "denominator" in this patient population.
Dr Mills. I am willing to accept that judicious EVT is unlikely to impact ability to perform bypass. However, I also am confident that quite a bit of injudicious infrainguinal endovascular therapy is being widely performed, so I am not sure the results you have reported today based on a single-center experience are generalizable.
